Intra-Cellular Therapies, Inc. (ITCI)
Chart Events
Performance Outlook
| Previous Close | 58.50 |
| Open | 58.75 |
| Bid | 58.88 x 800 |
| Ask | 59.08 x 1200 |
| Day's Range | 57.45 - 59.87 |
| 52 Week Range | 28.40 - 66.00 |
| Volume | |
| Avg. Volume | 962,798 |
| Market Cap | 4.823B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.
- Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
- Motley Fool
Why Intra-Cellular Therapies Trounced the S&P 500 Today
For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December. Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit.
